The adjustment in price target by a reputable analyst firm like Canaccord Genuity could have a mixed impact. While the maintenance of a Buy rating signals continued confidence in Ocuphire Pharma's fundamentals and future prospects, the reduction in the price target might reflect adjustments in market conditions or expectations regarding the company's performance. This could lead to short-term volatility in the stock price as investors reassess their expectations based on the new target. However, the overall positive stance is likely to support investor sentiment.